Reata Pharmaceuticals Performance
| RETADelisted Stock | USD 109.67 3.31 2.93% |
The company holds a Beta of -0.35, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Reata Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Reata Pharmaceuticals is likely to outperform the market. Reata Pharmaceuticals right now holds a risk of 0.0%. Please check Reata Pharmaceuticals downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to decide if Reata Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Reata Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Reata Pharmaceuticals is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 590.3 M | |
| Total Cashflows From Investing Activities | -345.2 M |
Reata |
Reata Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 10,967 in Reata Pharmaceuticals on August 24, 2024 and sell it today you would earn a total of 0.00 from holding Reata Pharmaceuticals or generate 0.0% return on investment over 90 days. Reata Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Reata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Reata Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reata Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reata Pharmaceuticals, and traders can use it to determine the average amount a Reata Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| RETA |
Based on monthly moving average Reata Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reata Pharmaceuticals by adding Reata Pharmaceuticals to a well-diversified portfolio.
Reata Pharmaceuticals Fundamentals Growth
Reata Stock prices reflect investors' perceptions of the future prospects and financial health of Reata Pharmaceuticals, and Reata Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reata Stock performance.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X | |||
| Price To Sales | 414.73 X | |||
| Revenue | 2.22 M | |||
| EBITDA | (269.02 M) | |||
| Cash And Equivalents | 481.47 M | |||
| Cash Per Share | 13.19 X | |||
| Total Debt | 119.46 M | |||
| Debt To Equity | 2.08 % | |||
| Book Value Per Share | 2.31 X | |||
| Cash Flow From Operations | (204.27 M) | |||
| Earnings Per Share | (2.62) X | |||
| Total Asset | 514.49 M | |||
| Retained Earnings | (1.57 B) | |||
| Current Asset | 87.28 M | |||
| Current Liabilities | 59.63 M | |||
About Reata Pharmaceuticals Performance
By analyzing Reata Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Reata Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Reata Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Reata Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.Things to note about Reata Pharmaceuticals performance evaluation
Checking the ongoing alerts about Reata Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reata Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reata Pharmaceuticals is not yet fully synchronised with the market data | |
| Reata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.22 M. Net Loss for the year was (311.9 M) with loss before overhead, payroll, taxes, and interest of (167.63 M). | |
| Reata Pharmaceuticals currently holds about 481.47 M in cash with (204.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.19. | |
| Over 88.0% of the company shares are owned by institutional investors |
- Analyzing Reata Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reata Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Reata Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reata Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reata Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reata Pharmaceuticals' stock. These opinions can provide insight into Reata Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |